School of Medicine


Showing 1-20 of 32 Results

  • Fahim Abbasi

    Fahim Abbasi

    Clinical Assistant Professor, Medicine - Cardiovascular Medicine

    BioDr. Fahim Abbasi specializes in diagnosis and treatment of prediabetes and insulin resistance. Dr. Abbasi has a special interest in prevention of diabetes and cardiovascular disease through lifestyle modifications.

  • Ranjana Advani

    Ranjana Advani

    Saul A. Rosenberg, MD, Professor of Lymphoma

    Current Research and Scholarly InterestsClinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.

    The research program is highly collaborative with radiation oncology, industry, pathology and dermatology.

  • Patrick Cunningham Ahearn, MD, MAS

    Patrick Cunningham Ahearn, MD, MAS

    Clinical Assistant Professor, Medicine - Nephrology

    BioDr. Ahearn is a board-certified nephrologist. He is also a clinical assistant professor in the Stanford University School of Medicine Division of Nephrology.

    He specializes in providing innovative care to kidney disease and transplant patients. He develops a comprehensive, compassionate care plan personalized to each patient in his care.

    In addition to his clinical practice, Dr. Ahearn has conducted research on barriers to transplantation for patients with extended dialysis exposure, disparities in living kidney donation, and disparities in access to kidney transplant. He also has researched kidney transplant outcomes as they relate to the timing of dialysis initiation plus new pharmaceuticals for the kidney transplant population.

    Dr. Ahearn has made presentations on these and other topics to the American Transplant Congress and Society of General Internal Medicine Meeting. He has published peer-reviewed articles on his research topics in the Clinical Journal of the American Society of Nephrology, JAMA Network Open, American Journal of Kidney Diseases, American Journal of Surgery, and elsewhere. He has published abstracts in the Journal of the American Society of Nephrology.

    Dr. Ahearn has earned honors for his research and scholarship. He has received research funding from the National Institute of Diabetes and Digestive and Kidney Diseases.
    Among his honors, Dr. Ahearn was on the kidney transplant team that earned the Stanford Health Care Integrated Strategic Plan Star Award. The team was recognized for delivering excellence in patient care as well as for identifying opportunities to improve care.

    He is a member of the American Society of Nephrology and American Society of Transplantation.

    He has volunteered his time and expertise as a board member of the Village of Hope, a transitional housing program for homeless men, women, and children in Orange County, California. Dr. Ahearn has served as a volunteer and proctor at the free clinic providing medical services to the uninsured.

  • Aijaz Ahmed, MD

    Aijaz Ahmed, MD

    Professor of Medicine (Gastroenterology and Hepatology)

    BioDr. Ahmed is an internationally recognized hepatologist with expertise in the treatment of acute and chronic liver diseases. He is a board-certified specialist in gastroenterology and hepatology, transplant hepatology, and obesity medicine. Currently, he serves as the Medical Director of the Adult Liver Transplant Program at Stanford University.

    Dr. Ahmed graduated from Dow Medical College, Karachi, Pakistan. He completed his residency training in Internal Medicine at Brown University, Providence, RI and fellowship training in Gastroenterology and Hepatology at Stanford University. During his fellowship, he focused on clinical and research training in General and Transplant Hepatology.

    For patients under his care, Dr. Ahmed remains dedicated to creating a personalized, comprehensive, and above-all a compassionate treatment plan. He outlines the diagnostic and follow-up management pathway in an individualized fashion; he updates his patients and their family/support at each step of the decision-making process; and he focuses on prioritizing the wishes of his patients and their family/support for an optimal outcome and quality of life.

    Dr. Ahmed remains clinically active and has been instrumental in establishing a wide network of hepatology outreach clinics in remote and underserved regions of California and Nevada.

    In addition to his patient care responsibilities, Dr. Ahmed remains committed to the educational mission of Stanford ford University. He remains deeply interested in mentoring trainees and students al levels from undergraduates to trainee physicians and junior colleagues. Dr. Ahmed has received several teaching awards during his career.

    Dr. Ahmed’s research interests include 1) multidisciplinary approach to nonalcoholic fatty liver disease (NAFLD), 2) disparities in the management of chronic liver disease, 3) improving screening and management of hepatocellular carcinoma (HCC), and 4) outcomes research in NAFLD, HCC, viral hepatitis, alcoholic liver disease, and liver transplantation. He heads a busy and productive outcomes research team. In addition, he collaborates with basic scientists and is participating in several translational research projects at Stanford University.

    He has published his findings in textbooks, abstracts, case reports, and high- profile medical journals including Gastroenterology, Journal of Hepatology, Hepatology American Journal of Gastroenterology, and other well-renowned peer-reviewed publications.

    Dr. Ahmed and his team has made presentations to his peers at many national and international conferences: the American Association for the Study of Liver Disease, International Liver Congress, European Association for the Study of the Liver, Asian Pacific Association for the Study of the Liver, and more. His presentations have addressed leading-edge approaches to the treatment of chronic liver disease, liver cancer, and liver failure. He also has presented his insights into the gastrointestinal impact of COVID-19.

    For his clinical, research, and teaching achievements, Dr. Ahmed has earned extensive recognition. His honors include being named as one of America’s Top Physicians by the Consumers’ Research Council of America.

    He is an active member of the American Gastroenterological Association and the American Association for the Study of Liver Diseases.

  • Neera Ahuja

    Neera Ahuja

    Professor of Medicine (Hospital Medicine)

    Current Research and Scholarly InterestsClinical inpatient trials, Quality improvement, Assessing interventions with operations on throughput. SDOH/Health equity
    Medical education research; Intergenerational teaching/learning; Analysis of effects of duty hour regulations on housestaff training and ways to improve the system

  • Kevin M. Alexander, MD, FACC, FHFSA

    Kevin M. Alexander, MD, FACC, FHFSA

    Assistant Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center

    BioDr. Alexander is an advanced heart failure-trained cardiologist. He is also an Assistant Professor of Cardiovascular Medicine at Stanford University School of Medicine.

    Dr. Alexander specializes in the management of advanced heart failure and transplant cases, seeing a wide range of patients. He also has an active research laboratory, studying various forms of heart failure.

    Dr. Alexander has expertise in diagnosing and treating transthyretin cardiac amyloidosis, a critical yet underdiagnosed cause of heart failure among African Americans and the elderly. He is conducting extensive research to enhance our understanding of this condition, with grant support from the National Institutes of Health and American Heart Association, among other sources.

  • Ash A. Alizadeh, MD/PhD

    Ash A. Alizadeh, MD/PhD

    Moghadam Family Professor

    Current Research and Scholarly InterestsMy research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.

    Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials.

  • Matthew Sievers Alkaitis

    Matthew Sievers Alkaitis

    Clinical Assistant Professor, Medicine

    BioMatthew S Alkaitis MD, PhD is is a Clinical Assistant Professor in the Division of Hospital medicine and Stanford School of Medicine. He received his PhD in biochemistry from the University of Oxford, in collaboration the National Institutes of Health as part of the NIH’s graduate partnership program. He received his MD from Harvard Medical school and completed his residency in internal medicine at Stanford. Dr. Alkaitis’ research interests span basic biochemistry, clinical informatics, natural language processing, genetics of hematologic malignancies and methods of cell-free DNA detection. His primary medical education interest is expanding accessibility of modern computational and bioinformatics techniques for clinical research.

  • Russ B. Altman

    Russ B. Altman

    Kenneth Fong Professor and Professor of Bioengineering, of Genetics, of Medicine, of Biomedical Data Science, Senior Fellow at the Stanford Institute for HAI and Professor, by courtesy, of Computer Science

    Current Research and Scholarly InterestsI refer you to my web page for detailed list of interests, projects and publications. In addition to pressing the link here, you can search "Russ Altman" on http://www.google.com/

  • Shuchi Anand

    Shuchi Anand

    Associate Professor of Medicine (Nephrology)

    Current Research and Scholarly InterestsManagement of CKD and ESRD in low-resource settings
    Tubulointerstitial disease
    Chronic kidney disease of unknown etiology
    ESRD and physical activity
    ESRD and vitamin D deficiency

  • Chad Anderson

    Chad Anderson

    Clinical Assistant Professor, Medicine - Primary Care and Population Health

    BioChad Anderson is a Physician Assistant at Stanford ValleyCare and a Clinical Assistant Professor with the Stanford School of Medicine MSPA program. He is the Assistant Director of PA education at ValleyCare. He is dual credentialed as a Family Nurse Practitioner and a Physician Assistant. He completed his FNP/PA training at the Stanford School of Medicine and his graduate studies at A.T. Still University – Arizona School of Health Sciences. He is passionate about improving our patients hospital experience as well as educating our future providers.

  • Jason Andrews

    Jason Andrews

    Professor of Medicine (Infectious Diseases)

    Current Research and Scholarly InterestsOur laboratory aims to develop and test innovative approaches to the diagnosis, treatment and control of infectious diseases in resource-limited settings. We draw upon multiple fields including mathematical modeling, microbial genetics, field epidemiology, statistical inference and biodesign to work on challenging problems in infectious diseases, with an emphasis on tuberculosis and tropical diseases.

  • Justin P. Annes M.D., Ph.D.

    Justin P. Annes M.D., Ph.D.

    Associate Professor of Medicine (Endocrinology)

    Current Research and Scholarly InterestsThe ANNES LABORATORY of Molecular Endocrinology: Leveraging Chemical Biology to Treat Endocrine Disorders

    DIABETES
    The prevalence of diabetes is increasing at a staggering rate. By the year 2050 an astounding 25% of Americans will be diabetic. The goal of my research is to uncover therapeutic strategies to stymie the ensuing diabetes epidemic. To achieve this goal we have developed a variety of innovate experimental approaches to uncover novel approaches to curing diabetes.

    (1) Beta-Cell Regeneration: Diabetes results from either an absolute or relative deficiency in insulin production. Our therapeutic strategy is to stimulate the regeneration of insulin-producing beta-cells to enhance an individual’s insulin secretion capacity. We have developed a unique high-throughput chemical screening platform which we use to identify small molecules that promote beta-cell growth. This work has led to the identification of key molecular pathways (therapeutic targets) and candidate drugs that promote the growth and regeneration of islet beta-cells. Our goal is to utilize these discoveries to treat and prevent diabetes.

    (2) The Metabolic Syndrome: A major cause of the diabetes epidemic is the rise in obesity which leads to a cluster of diabetes- and cardiovascular disease-related metabolic abnormalities that shorten life expectancy. These physiologic aberrations are collectively termed the Metabolic Syndrome (MS). My laboratory has developed an original in vivo screening platform t to identify novel hormones that influence the behaviors (excess caloric consumption, deficient exercise and disrupted sleep-wake cycles) and the metabolic abnormalities caused by obesity. We aim to manipulate these hormone levels to prevent the development and detrimental consequences of the MS.

    HEREDIATY PARAGAGLIOMA SYNDROME
    The Hereditary Paraganglioma Syndrome (hPGL) is a rare genetic cancer syndrome that is most commonly caused by a defect in mitochondrial metabolism. Our goal is to understand how altered cellular metabolism leads to the development of cancer. Although hPGL is uncommon, it serves as an excellent model for the abnormal metabolic behavior displayed by nearly all cancers. Our goal is to develop novel therapeutic strategies that target the abnormal behavior of cancer cells. In the laboratory we have developed hPGL mouse models and use high throughput chemical screening to identify the therapeutic susceptibilities that result from the abnormal metabolic behavior of cancer cells.

    As a physician scientist trained in clinical genetics I have developed expertise in hereditary endocrine disorders and devoted my efforts to treating families affected by the hPGL syndrome. By leveraging our laboratory expertise in the hPGL syndrome, our care for individuals who have inherited the hPGL syndrome is at the forefront of medicine. Our goal is to translate our laboratory discoveries to the treatment of affected families.